Blueprint Medicines Corporation
BPMC
$88.48
-$0.03-0.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 11.23% | -12.56% | -156.09% | 180.36% | 17.05% |
| Total Depreciation and Amortization | 3.57% | 6.80% | -24.80% | 214.17% | -46.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.67% | -7.18% | 116.49% | -859.27% | -14.26% |
| Change in Net Operating Assets | -165.56% | 157.68% | 37.95% | -515.25% | 250.07% |
| Cash from Operations | -115.33% | 71.63% | 52.64% | -28.61% | 24.46% |
| Capital Expenditure | -3,628.00% | 99.03% | -132.70% | 76.37% | 25.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.56% | 116.14% | -337.39% | -6.24% | 2,602.01% |
| Cash from Investing | 12.55% | 115.91% | -344.12% | -2.08% | 921.71% |
| Total Debt Issued | -- | -100.00% | -- | -- | -100.04% |
| Total Debt Repaid | -- | 100.00% | 53.39% | -738.64% | -- |
| Issuance of Common Stock | -46.90% | -41.12% | -53.65% | 331.42% | 3,521.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -46.90% | -89.68% | 165.84% | 331.24% | -84.22% |
| Foreign Exchange rate Adjustments | -324.03% | 2,006.45% | 78.62% | -129.77% | 190.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -63.78% | 160.43% | -237.58% | 167.63% | 197.81% |